General
Preferred name
PRANLUKAST
Synonyms
ONO-1078 ()
ONO1078 hemihydrate ()
ONO-1078 hemihydrate ()
ONO 1078 ()
Pranlukast (hemihydrate) ()
ONO-1078 (hemihydrate) ()
Pranlukast (ONO 1078) ()
Pranlukast hemihydrate ()
SB-205312 ()
CCN-00401 ()
CCN 00401 ()
Onon ()
AZLAIRE ()
SB 205312 ()
RS 411 ()
RS-411 ()
Pranlukast-d4 ()
ONON ()
P&D ID
PD012151
CAS
103177-37-3
150821-03-7
2713172-43-9
Tags
available
drug
Approved by
PMDA
First approval
2007
1995
Drug indication
sinusitis
Asthma
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Pranlukast is a leukotriene receptor antagonist (LTRA), with selectivity for cysteinyl leukotriene receptor 1 (CysLT1 receptor). It is estimated to be 4500-fold selective for CysLT1 over CysLT2 in vitro .
(GtoPdb)
DESCRIPTION
Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63¡À0.11, 0.99¡À0.19, and 5640¡À680 nM, respectively.
PRICE
29
DESCRIPTION
Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63¡À0.11, 0.99¡À0.19, and 5640¡À680 nM, respectively.
PRICE
29
DESCRIPTION
CCK1 antagonist; active in vivo
(Tocris Bioactive Compound Library)
DESCRIPTION
Pranlukast (ONO-1078) is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Pranlukast hemihydrate (ONO-1078 hemihydrate) is a selective and potent leukotriene (LT) antagonist with anti-asthmatic activity that inhibits [3H]LTD4 and [3H]LTE4 binding to lung membranes and antagonizes LTC4-induced constriction of guinea-pig airways.Pranlukast hemihydrate is used in the study of asthma. Pranlukast hemihydrate is used in the study of asthma.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
1
Compound Sets
24
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
52
Molecular Weight
481.18
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
9
Ring Count
5
Aromatic Ring Count
5
cLogP
4.63
TPSA
123.0
Fraction CSP3
0.15
Chiral centers
0.0
Largest ring
6.0
QED
0.29
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CysLTR
Eosinophil cationic protein
IL-5
Leukotriene Receptor
Mucin-2
NF-κB
TNF-α
Endogenous Metabolite
CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF
Primary Target
Leukotriene and Related Receptors
MOA
Antagonist
Leukotriene Receptor Antagonist
Pathway
GPCR/G protein
Apoptosis
Immunology/Inflammation
Metabolism
Metabolic Enzyme/Protease
Indication
bronchospasm, asthma
Therapeutic Class
Antiasthmatic Agents
Recommended Cell Concentration
100 nM
Source data
